Sridharrao B, Badrinath S S
Vision Research Foundation, Madras, India.
Br J Ophthalmol. 1989 Nov;73(11):884-7. doi: 10.1136/bjo.73.11.884.
The efficacy of 1.0% apraclonidine (para-aminoclonidine) in preventing the rise of intraocular pressure following anterior segment, laser surgery was evaluated in a randomised double-masked study. Ninety-nine consecutive patients requiring laser treatment of the anterior segment were included in the study. They were randomised into two groups, one receiving 1.0% para-aminoclonidine and the other placebo (vehicle of para-aminoclonidine). The drug caused a statistically significant reduction in pressure after the laser treatment without causing clinically significant side effects such as bradycardia or hypotension.
在一项随机双盲研究中,评估了1.0%阿可乐定(对氨基可乐定)预防眼前节激光手术后眼压升高的疗效。该研究纳入了99例连续需要进行眼前节激光治疗的患者。他们被随机分为两组,一组接受1.0%对氨基可乐定,另一组接受安慰剂(对氨基可乐定的赋形剂)。该药物在激光治疗后使眼压有统计学意义的降低,且未引起如心动过缓或低血压等具有临床意义的副作用。